UNLABELLED: Carbon-11-methoxyprogabidic acid (11C-MPGA) was recently synthetized as a possible ligand for PET studies of gamma-amino-butyric acid (GABA) receptors in the brain. The data for human absorbed dose estimates are calculated based on the biodistribution of 11C-MPGA in mice and humans. METHODS: Eighteen mice were killed at preset time intervals after an intravenous bolus injection of 3.7 MBq (100 microCi) 11C-MPGA. Time-activity curves were reconstructed for several organs. Three healthy men each had whole-body PET scans after an intravenous bolus injection of 37 MBq (1 mCi) to determine activity in the critical organs. Animal data were fitted into these human findings to calculate residence times, and the MIRDOSE 3 protocol was used to calculate the radiation absorbed dose. RESULTS: Animal studies demonstrated a rapid distribution of 11C-MPGA in several organs. The highest activity was detected in the intestines, liver and kidneys. Brain activity was low throughout compared to these organs. The human whole-body study yielded similar results, with the intestines, liver and kidneys showing the highest activity. The estimated dose to the urinary bladder compartment turned out to be significant. The mean effective dose was 4.8 microSv/MBq (s.d.= 0.5 microSv/MBq). CONCLUSION: PET studies using 185 MBq (5 mCi) 11C-MPGA are within the International Commission on Radiological Protection risk Category II for healthy volunteers.
UNLABELLED: Carbon-11-methoxyprogabidic acid (11C-MPGA) was recently synthetized as a possible ligand for PET studies of gamma-amino-butyric acid (GABA) receptors in the brain. The data for human absorbed dose estimates are calculated based on the biodistribution of 11C-MPGA in mice and humans. METHODS: Eighteen mice were killed at preset time intervals after an intravenous bolus injection of 3.7 MBq (100 microCi) 11C-MPGA. Time-activity curves were reconstructed for several organs. Three healthy men each had whole-body PET scans after an intravenous bolus injection of 37 MBq (1 mCi) to determine activity in the critical organs. Animal data were fitted into these human findings to calculate residence times, and the MIRDOSE 3 protocol was used to calculate the radiation absorbed dose. RESULTS: Animal studies demonstrated a rapid distribution of 11C-MPGA in several organs. The highest activity was detected in the intestines, liver and kidneys. Brain activity was low throughout compared to these organs. The human whole-body study yielded similar results, with the intestines, liver and kidneys showing the highest activity. The estimated dose to the urinary bladder compartment turned out to be significant. The mean effective dose was 4.8 microSv/MBq (s.d.= 0.5 microSv/MBq). CONCLUSION: PET studies using 185 MBq (5 mCi) 11C-MPGA are within the International Commission on Radiological Protection risk Category II for healthy volunteers.
Authors: Adam L Kesner; Wei-Ann Hsueh; Johannes Czernin; Henry Padgett; Michael E Phelps; Daniel H S Silverman Journal: Mol Imaging Biol Date: 2008-08-05 Impact factor: 3.488
Authors: Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236
Authors: Tuula Tolvanen; Timo Yli-Kerttula; Tiina Ujula; Anu Autio; Pertti Lehikoinen; Heikki Minn; Anne Roivainen Journal: Eur J Nucl Med Mol Imaging Date: 2010-01-13 Impact factor: 9.236
Authors: Anu Autio; Helena Virtanen; Tuula Tolvanen; Heidi Liljenbäck; Vesa Oikonen; Tiina Saanijoki; Riikka Siitonen; Meeri Käkelä; Andrea Schüssele; Mika Teräs; Anne Roivainen Journal: EJNMMI Res Date: 2015-07-17 Impact factor: 3.138